NASDAQ:RIGL

Rigel Pharmaceuticals Stock Forecast, Price & News

$3.58
-0.20 (-5.29 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$3.53
Now: $3.58
$3.79
50-Day Range
$3.09
MA: $3.75
$4.47
52-Week Range
$1.45
Now: $3.58
$5.50
Volume2.96 million shs
Average Volume3.90 million shs
Market Capitalization$609.03 million
P/E RatioN/A
Dividend YieldN/A
Beta1.48
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is in phase III clinical trial for the treatment of warm autoimmune hemolytic anemia; phase II clinical trial for the treatment of hospitalized COVID-19 patients; and phase II clinical trial for the treatment of COVID-19. In addition, the company is developing R835, an oral interleukin receptor associated kinase 1/4 inhibitor, which is in phase I clinical trial for autoimmune, inflammatory, and hematology-oncology diseases; and R552, a receptor-interacting serine/threonine-protein kinase 1 inhibitor that has completed phase I clinical trial for autoimmune and inflammatory diseases. It has research and license agreements with Aclaris Therapeutics International Limited for the development and commercialization of janus kinase (JAK) inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled JAK inhibitor; BerGenBio AS for the development and commercialization of AXL inhibitors in oncology; and Daiichi Sankyo to develop murine double minute 2 inhibitors for solid and hematological malignancies, as well as license and supply agreement with Kissei Pharmaceutical Co., Ltd. to develop and commercialize Fostamatinib. The company also has a license agreement and strategic collaboration with Eli Lilly and Company to co-develop and commercialize R552 for various indications, including autoimmune and inflammatory diseases, as well as other non-central nervous system (non-CNS) disease development candidates. Rigel Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in South San Francisco, California.
Rigel Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Current SymbolNASDAQ:RIGL
CUSIP76655960
Phone650-624-1100
Employees169
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$59.29 million
Book Value$0.32 per share

Profitability

Net Income$-66,890,000.00

Miscellaneous

Market Cap$609.03 million
Next Earnings Date5/4/2021 (Estimated)
OptionableOptionable

Headlines

Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Down to $3.61
April 14, 2021 |  americanbankingnews.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up to $3.09
April 13, 2021 |  americanbankingnews.com
Rigel Pharmaceuticals (NASDAQ:RIGL) Shares Gap Up to $3.34
April 7, 2021 |  americanbankingnews.com
See More Headlines

MarketRank

Overall MarketRank

1.57 out of 5 stars

Medical Sector

428th out of 2,025 stocks

Pharmaceutical Preparations Industry

208th out of 772 stocks

Analyst Opinion: 3.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$3.58
-0.20 (-5.29 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RIGL News and Ratings via Email

Sign-up to receive the latest news and ratings for RIGL and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Rigel Pharmaceuticals (NASDAQ:RIGL) Frequently Asked Questions

Is Rigel Pharmaceuticals a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Rigel Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Rigel Pharmaceuticals stock.
View analyst ratings for Rigel Pharmaceuticals
or view top-rated stocks.

What stocks does MarketBeat like better than Rigel Pharmaceuticals?

Wall Street analysts have given Rigel Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Rigel Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Rigel Pharmaceuticals?

Rigel Pharmaceuticals saw a increase in short interest in March. As of March 31st, there was short interest totaling 22,030,000 shares, an increase of 30.6% from the March 15th total of 16,870,000 shares. Based on an average daily volume of 3,730,000 shares, the days-to-cover ratio is presently 5.9 days.
View Rigel Pharmaceuticals' Short Interest
.

When is Rigel Pharmaceuticals' next earnings date?

Rigel Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, May 4th 2021.
View our earnings forecast for Rigel Pharmaceuticals
.

How were Rigel Pharmaceuticals' earnings last quarter?

Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) announced its quarterly earnings data on Monday, March, 1st. The biotechnology company reported ($0.11) EPS for the quarter, meeting analysts' consensus estimates of ($0.11). The biotechnology company had revenue of $18.45 million for the quarter, compared to the consensus estimate of $18.37 million. Rigel Pharmaceuticals had a negative trailing twelve-month return on equity of 44.96% and a negative net margin of 26.25%. During the same quarter in the previous year, the company earned ($0.10) EPS.
View Rigel Pharmaceuticals' earnings history
.

How has Rigel Pharmaceuticals' stock been impacted by COVID-19?

Rigel Pharmaceuticals' stock was trading at $1.81 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, RIGL stock has increased by 97.8% and is now trading at $3.58.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for RIGL?

4 Wall Street analysts have issued twelve-month price targets for Rigel Pharmaceuticals' stock. Their forecasts range from $6.00 to $11.00. On average, they anticipate Rigel Pharmaceuticals' stock price to reach $8.33 in the next twelve months. This suggests a possible upside of 132.8% from the stock's current price.
View analysts' price targets for Rigel Pharmaceuticals
or view top-rated stocks among Wall Street analysts.

Who are Rigel Pharmaceuticals' key executives?

Rigel Pharmaceuticals' management team includes the following people:
  • Mr. Raul R. Rodriguez, Pres, CEO & Director (Age 60, Pay $1.01M)
  • Mr. Dean L. Schorno CPA, Exec. VP & CFO (Age 58, Pay $612.53k)
  • Ms. Dolly A. Vance, Exec. VP of Corp. Affairs, Gen. Counsel & Corp. Sec. (Age 56, Pay $761.28k)
  • Dr. Esteban S. Masuda, Exec. VP of Research (Age 59, Pay $537.21k)
  • Dr. Wolfgang Dummer M.D., Ph.D., Exec. VP & Chief Medical Officer (Age 55, Pay $170.22k)
  • Mr. Joseph Lasaga, Sr. VP of Corp. Devel. (Age 46)
  • Ms. Lily Cheung, VP of HR
  • Mr. David A. Santos, Exec. VP & Chief Commercial Officer
  • Mr. Tarek Sallam, VP of Marketing

What is Raul Rodriguez's approval rating as Rigel Pharmaceuticals' CEO?

6 employees have rated Rigel Pharmaceuticals CEO Raul Rodriguez on Glassdoor.com. Raul Rodriguez has an approval rating of 84% among Rigel Pharmaceuticals' employees.

Who are some of Rigel Pharmaceuticals' key competitors?

What other stocks do shareholders of Rigel Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Rigel Pharmaceuticals investors own include ADMA Biologics (ADMA), Matinas BioPharma (MTNB), Zosano Pharma (ZSAN), Sorrento Therapeutics (SRNE), Aeterna Zentaris (AEZS), KushCo (KSHB), Novan (NOVN), Bionano Genomics (BNGO), OrganiGram (OGI) and Pennsylvania Real Estate Investment Trust (PEI).

What is Rigel Pharmaceuticals' stock symbol?

Rigel Pharmaceuticals trades on the NASDAQ under the ticker symbol "RIGL."

How do I buy shares of Rigel Pharmaceuticals?

Shares of RIGL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Rigel Pharmaceuticals' stock price today?

One share of RIGL stock can currently be purchased for approximately $3.58.

How much money does Rigel Pharmaceuticals make?

Rigel Pharmaceuticals has a market capitalization of $609.03 million and generates $59.29 million in revenue each year. The biotechnology company earns $-66,890,000.00 in net income (profit) each year or ($0.40) on an earnings per share basis.

How many employees does Rigel Pharmaceuticals have?

Rigel Pharmaceuticals employs 169 workers across the globe.

What is Rigel Pharmaceuticals' official website?

The official website for Rigel Pharmaceuticals is www.rigel.com.

Where are Rigel Pharmaceuticals' headquarters?

Rigel Pharmaceuticals is headquartered at 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080.

How can I contact Rigel Pharmaceuticals?

Rigel Pharmaceuticals' mailing address is 1180 VETERANS BOULEVARD, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-624-1100 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.